Results 121 to 130 of about 1,081,297 (374)
Meningococcal conjugate vaccines: optimizing global impact
Infection and Drug Resistance, 2011 Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2 1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for ...
Terranella A, Cohn A, Clark T
doaj
13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
Вопросы современной педиатрии, 2012 The data on efficacy and safety of 7- and 13-valent pneumococcal conjugate vaccines are shown in this article. The authors have analyzed the experience of immunization with 13-valent vaccine Prevenar.
V. K. Tatochenko +1 more
doaj +1 more source
The Update, February 13, 2012 [PDF]
, 2012 The Update is a bi-weekly web newsletter published by the Iowa Department of Public Health's Bureau of Family Health. It is posted the second and fourth week of every month, and provides useful job resource information for departmental health care ...
core
Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction [PDF]
, 2019 Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies.
Bernstein, David I. +5 more
core +1 more source
Lymphoid and CXCR4 Cell Targeted Lipid Nanoparticles Facilitate HIV‐1 Proviral DNA Excision
Advanced Healthcare Materials, EarlyView.Advancements in ART improve HIV‐1 patient outcomes but are unable to eliminate latent viral DNA. To address this, CXCR4‐targeted lipid nanoparticles (T‐LNPs) for delivering CRISPR‐Cas9 to excise HIV‐1 DNA in infected cells are developed. These T‐LNPs achieve ≈60% HIV‐1 DNA excision efficacy in blood and splenic tissue, demonstrating promise for ...
Sudipta Panja +6 more
wiley +1 more source
Biomedical Journal, 2012 The 7-valent pneumococcal conjugate vaccine (PCV7) is currently being introduced in the vaccine schedule of over 90 countries around the world. After the introduction of the PCV7 vaccine in the United States, a reduction of more than 90% of invasive ...
Oana Falup-Pecurariu
doaj +1 more source
Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice [PDF]
, 2018 Hepatitis C virus (HCV) is a globally disseminated human pathogen for which no vaccine is currently available. HCV is highly diverse genetically and can be classified into 7 genotypes and multiple sub-types. Due to this antigenic variation, the induction
Bieńkowska-Szewczyk, Krystyna +5 more
core +1 more source
Clinical Infectious Diseases, 2015 Background. A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African “meningitis belt” and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali,
M. Djingarey +10 more
semanticscholar +1 more source
Multiscale Profiling of Nanoscale Metal‐Organic Framework Biocompatibility and Immune Interactions
Advanced Healthcare Materials, EarlyView.A multi‐scale, hierarchical ‘Safety‐by‐Design’ pipeline combining machine learning, ex vivo human blood assays, and in vivo models enables the systematic immunotoxicity and biocompatibility profiling of nanoscale metal‐organic frameworks, accelerating their safe clinical translation. Abstract The clinical translation of metal‐organic frameworks (MOFs) –
Yunhui Zhuang +12 more
wiley +1 more source
Uptake of Pneumococcal Vaccines Among U.S. Adults After 2022 Update to Recommendations
AJPM FocusIntroduction: Updated recommendations for adult pneumococcal vaccination in the U.S. (publication date: January 27, 2022) incorporated 2 new vaccines (15- and 20-valent pneumococcal conjugate vaccines), removed 13-valent pneumococcal conjugate vaccine ...
Ahuva Averin, MPP +5 more
doaj